NovaBridge Hires Mark Hagler to Drive Commercialization of Givastomig and VIS-101
NovaBridge appointed Mark Hagler as President and Chief Commercial Officer to lead commercial strategy and maximize value of its givastomig and VIS-101 pipelines. Hagler brings over 25 years of biopharma leadership, including launching Abraxane and Afinitor, to shape clinical trial design and drive pre-commercial readiness.
1. Executive Appointment
NovaBridge has named Mark Hagler as President and Chief Commercial Officer. In this role, he will oversee commercial strategy, inform clinical trial design, and lead business development to maximize the value of the givastomig and VIS-101 pipelines.
2. Hagler's Commercial Track Record
Over a 25-year career, Hagler led the global launch of Abraxane and a core Afinitor indication, scaled a $1B+ oncology portfolio at Sun Pharmaceuticals and drove profitability for its U.S. operations. He also transformed an ophthalmology division, established operational standards and executed acquisitions to expand market reach.
3. Pipeline Strategy and Outlook
NovaBridge is advancing givastomig toward registrational pivotal studies in first-line gastric cancer following positive Phase 1b data and plans a Phase 2b dose study for VIS-101 in wet AMD in H2 2026. Hagler will shape pre-commercial readiness and cross-functional collaboration to position both assets for market success.